Experienced in ALK-Positive Non-Small Cell Lung Cancer

Dr. Everett C. Ribakove

Hematology Oncology | Hospital Medicine | Hematology
Unc Physicians Network LLC
516 S Van Buren Rd, 
Eden, NC 
Accepting New Patients
Offers Telehealth
Experienced in ALK-Positive Non-Small Cell Lung Cancer
Unc Physicians Network LLC
516 S Van Buren Rd, 
Eden, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Everett Ribakove is a Hematologist Oncology specialist and a Hospital Medicine provider in Eden, North Carolina. Dr. Ribakove is rated as an Experienced provider by MediFind in the treatment of ALK-Positive Non-Small Cell Lung Cancer. His top areas of expertise are Chronic Myelomonocytic Leukemia (CMML), Iron Deficiency Anemia, Childhood Iron Deficiency Anemia, and Lung Cancer. Dr. Ribakove is currently accepting new patients.

His clinical research consists of participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hospital Medicine
Hematology
Licenses
Internal Medicine in NC
Hospital Affiliations
Unc Hospitals
Southeastern Regional Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

UNC PHYSICIANS NETWORK LLC
516 S Van Buren Rd, Eden, NC 27288

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab, Sargramostim
Study Phase: Phase 2/Phase 3
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: May 21, 2025
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Other
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: June 23, 2021
Intervention Type: Other, Drug
Study Drug: Talazoparib
Study Phase: Phase 2
A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
Enrollment Status: Terminated
Publish Date: January 20, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
Enrollment Status: Terminated
Publish Date: September 11, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2
View 6 Less Clinical Trials
Similar Doctors
Distinguished in ALK-Positive Non-Small Cell Lung Cancer
Dr. Jeffrey A. Crawford
Hematology Oncology | Hematology | Oncology
Distinguished in ALK-Positive Non-Small Cell Lung Cancer
Dr. Jeffrey A. Crawford
Hematology Oncology | Hematology | Oncology

Duke Health Integrated Practice Inc

2351 Erwin Rd, 
Durham, NC 
 (55.9 miles away)
919-684-8111
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeffrey Crawford is a Hematologist Oncology specialist and a Hematologist in Durham, North Carolina. Dr. Crawford is rated as a Distinguished provider by MediFind in the treatment of ALK-Positive Non-Small Cell Lung Cancer. His top areas of expertise are ALK-Positive Non-Small Cell Lung Cancer, Lung Adenocarcinoma, Squamous Cell Lung Carcinoma, and Small Cell Lung Cancer (SCLC). Dr. Crawford is currently accepting new patients.

Distinguished in ALK-Positive Non-Small Cell Lung Cancer
Dr. Mohamed K. Mohamed
Hematology | Oncology
Distinguished in ALK-Positive Non-Small Cell Lung Cancer
Dr. Mohamed K. Mohamed
Hematology | Oncology

The Moses H Cone Memorial Hospital Operating Corporation

501 N Elam Ave, 
Greensboro, NC 
 (28.9 miles away)
336-832-1100
Languages Spoken:
English, Arabic
See accepted insurances
Accepting New Patients
Offers Telehealth

Mohamed Mohamed is a Hematologist and an Oncologist in Greensboro, North Carolina. Dr. Mohamed is rated as a Distinguished provider by MediFind in the treatment of ALK-Positive Non-Small Cell Lung Cancer. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Pleuropulmonary Blastoma, and EGFR Positive Lung Cancer. Dr. Mohamed is currently accepting new patients.

Distinguished in ALK-Positive Non-Small Cell Lung Cancer
Dr. Vandana R. Karri
Hematology Oncology | Hematology | Oncology
Distinguished in ALK-Positive Non-Small Cell Lung Cancer
Dr. Vandana R. Karri
Hematology Oncology | Hematology | Oncology

Lewis Gale Physicians LLC

1802 Braeburn Dr, 
Salem, VA 
 (55.4 miles away)
540-772-3400
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Vandana Karri is a Hematologist Oncology specialist and a Hematologist in Salem, Virginia. Dr. Karri is rated as a Distinguished provider by MediFind in the treatment of ALK-Positive Non-Small Cell Lung Cancer. Her top areas of expertise are Small Cell Lung Cancer (SCLC), Childhood Iron Deficiency Anemia, Lung Cancer, and Pleuropulmonary Blastoma. Dr. Karri is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ribakove's expertise for a condition
ConditionClose
      View All 106 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile